Medpace Holdings, Inc.
MEDP
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $16.6B
$592.40
▼ -0.10%
P/E
34.58
Mkt Cap
$16.6B
52-Wk Range
$373.00–$677.90
52-Week Range
$373.00 - $677.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 23.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated full-service platform reducing client complexity and improving efficiency
- Established relationships with pharmaceutical and biotech sponsors built over 30+ years
- Specialized expertise across multiple therapeutic areas and trial phases
- Global infrastructure enabling multi-region trial execution and regulatory navigation
Bear Case
2 risks
- Average volatility.
- Premium valuation to Life Sciences Tools peers
Growth
Stable outlook
Increasing pharmaceutical R&D spending and clinical trial outsourcing adoption
Value
Premium valuation to Life Sciences Tools peers
Momentum
Hot
+31.5% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying MEDP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 22, 2026
Reported EPS of $4.25 vs $3.98 consensus (+6.8% surprise). Revenue of $707.3M vs $689.5M expected (+2.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.8%
Revenue trend · last 8Q
—
+8%
+9%
+14%
+24%
+32%
+27%
+17%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$533.3M
$536.6M
$558.6M
$603.3M
$659.9M
$708.5M
$706.6M
$707.3M
Margins · last 8Q
Gross
28.5%
Operating
20.8%
Profit
17.2%
Wall Street consensus
7 analysts · 29% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
29%
Hold
71%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Jul 24, 2026
vs Industry
How MEDP stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related